Li Zhengxing, Hu Yuewen, Xu Chang, Zou Zixiu, Sun Zhenyu, Gao Zhunyi, Xiao Man, Guo Shicheng, Wang Yi, Wang Haijian, Wang Zhiping, Li Qiang, Shen Bo, Song Yuanlin, Wu Junjie
Department of Surgery, Navy Military Medical University Affiliated to Changhai Hospital, Shanghai, 200433 China.
Department of Outpatient, Chinese People's Liberation Army 92914 Army Hospital, Hainan, 571833 China.
Phenomics. 2024 Oct 8;4(5):453-464. doi: 10.1007/s43657-024-00171-z. eCollection 2024 Oct.
Lung cancer remains the leading cause of death among cancer patients, and the five-year survival rate is less than 25%. However, () polymorphism rs140693 predicts the prognosis of lung cancer patients still needs further verification. Primary lung cancer patients ( = 839) were collected from two hospitals, genomic DNA was extracted from blood, and genotyping was performed using SNPcan technology. Kaplan-Meier technique and multivariate Cox proportional hazards model were used to analyze the prognosis association between and clinical characteristics. Significantly conferred a poorer prognosis was associated with the CT genotype (CT vs. CC; adjusted hazard ratio [HR] = 1.21, 95% CI: 1.03-1.43, = 0.023) and dominant CT + TT genotype (CT + TT vs. CC; HR = 1.19, 95% CI: 1.02-1.39, = 0.029) of polymorphism rs140693 for all lung cancer patients, compared with the CC genotype. Stratified analysis showed that polymorphism rs140693 CT and dominant CT + TT genotype conferred a significantly poorer prognosis in female and lung adenocarcinoma (ADC) cancer patients, compared with the CC genotype. Non-small cell lung cancer (NSCLC) patients with the CT genotype had a poorer prognosis than those with the CC genotype. Additionally, the allele T of small cell lung cancer (SCLC) patients compared with the allele C was associated with a poor prognosis, and the CT and recessive TT genotype of SCLC patients conferred a significantly poor prognosis. The polymorphism rs140693 is a significant prognostic genetic marker for predicting the prognosis of lung cancer patients.
The online version contains supplementary material available at 10.1007/s43657-024-00171-z.
肺癌仍然是癌症患者死亡的主要原因，且五年生存率低于25%。然而，（）多态性rs140693对肺癌患者预后的预测仍需进一步验证。从两家医院收集了原发性肺癌患者（n = 839），从血液中提取基因组DNA，并使用SNPcan技术进行基因分型。采用Kaplan-Meier技术和多变量Cox比例风险模型分析（）与临床特征之间的预后关联。与CC基因型相比，对于所有肺癌患者，多态性rs140693的CT基因型（CT与CC；调整后风险比[HR] = 1.21，95%可信区间：1.03 - 1.43，P = 0.023）和显性CT + TT基因型（CT + TT与CC；HR = 1.19，95%可信区间：1.02 - 1.39，P = 0.029）显著预示着较差的预后。分层分析表明，与CC基因型相比，多态性rs140693的CT和显性CT + TT基因型在女性和肺腺癌（ADC）患者中预示着显著较差的预后。CT基因型的非小细胞肺癌（NSCLC）患者的预后比CC基因型患者差。此外，小细胞肺癌（SCLC）患者的等位基因T与等位基因C相比与预后不良相关，且SCLC患者的CT和隐性TT基因型预示着显著不良的预后。多态性rs140693是预测肺癌患者预后的一个重要预后遗传标志物。
在线版本包含可在10.1007/s43657 - 024 - 00171 - z获取的补充材料。
